CIMS - CASE 3

Question 1

Which of the following genes are considered to have high hazard ratios as predisposing factors of SLE

a. DR3
b. HLA-DRB1
c. TCF7
d. TREX1

Answer 1

D

Question 2

It is a genetic “signature” in whole blood, peripheral blood cells, skin lesions, synovium and kidneys that is associated with active disease

a. IL2
b. IFNa
c. TNFa
d. BAFF

Answer 2

B

Question 3

It is an antibody that is specific for SLE

a. Anti-Ro
b. ANA
c. Antiphospholipid
d. Anti-Sm

Answer 3

D

Question 4

The following classes of lupus nephritis should be treated with aggressive immunosuppression because of high risk of ESRD, except:

a. class II
b. class III
c. class IV
d. class V

Answer 4

A

Question 5

> 90% of glomeruli globally sclerosed without residual activity

a. class III
b. class IV
c. class V
d. class VI

Answer 5

D

Question 6

Patients with which of the following may fulfill the criteria for both RA and SLE – rhupus

a. polyarthritis
b. joint derfomities
c. erosions
d. ischemic bone necrosis

Answer 6

C

Question 7

It is the most common chronic dermatitis in lupus

a. discoid lupus erythematosus
b. “butterfly” rash
c. subacute cutaneous lupus erythematosus
d. lupus profundus

Answer 7

A

“butterfly” rash - acute

Question 8

Most serious manifestation of SLE

a. Libman-Sacks endocarditis
b. nephritis
c. pleuritis
d. pericarditis

Answer 8

B

Question 9

Most common manifestation of diffuse CNS lupus

a. cognitive dysfunction
b. seizure
c. psychosis
d. myelopathy

Answer 9

A

Question 10

Life threatening pulmonary manifestations of SLE, except:

a. interstitial inflammation
b. shrinking lung syndrome
c. intra-alveolar hemorrhage
d. pulmonary infiltrates

Answer 10

D

Question 11

Most frequent hematologic manifestation of SLE

a. leukopenia
b. lymphopenia
c. thrombocytopenia
d. anemia

Answer 11

D

Question 12

Serious ocular manifestation of SLE

a. Sicca syndrome
b. conjunctivitis
c. renal vasculitis
d. optic neuritis

Answer 12

D

retinal vasculitis

Question 13

Most important autoantibodies

a. Anti-Ro
b. ANA
c. Anti-dsDNA
d. Anti-Sm

Answer 13

B

Question 14

These identify patients at risk for venous arterial clotting, thrombocytopenia, and fetal loss

a. ANA
b. Anti-Sm
c. Antiphospholipid
d. Anti-Ro

Answer 14

C

Question 15

It indicates increased risk for neonatal lupus, sicca syndrome, and SCLE

a. ANA
b. Anti-Sm
c. Antiphospholipid
d. Anti-Ro

Answer 15

D

Question 16

Adverse effect of hydroxychloroquine

a. ototoxicity
b. renal toxicity
c. retinal toxicity
d. pulmonary toxicity

Answer 16

C

Question 17

It is highly effective in patients with lupus dermatitis

a. belimumab
b. mycophenolate mofetil
c. anifrolumab
d. methotrexate

Answer 17

C

Question 18

Adverse effect of mycophenolate mofetil

a. diarrhea
b. amenorrhea
c. leukopenia
d. nausea

Answer 18

A

others: cyclophosphamide

Question 19

Maintenance therapy that can maintain renal function

a. azathioprine
b. mycophenolate mofetil
c. cyclophosphamide
d. methotrexate

Answer 19

B

Question 20

Can be used to control active SLE in pregnant patients

a. azathioprine
b. mycophenolate mofetil
c. cyclophosphamide
d. methotrexate

Answer 20

A

Question 21

SLE in pregnant women can be controlled by the following, except:

a. dexamethasone
b. hydroxychloroquine
c. prednisone
d. azathioprine

Answer 21

A

fluorinated steroids should be avoided in pregnant patients: betamethasone

Question 22

Most common and less specific pattern of ANA

a. homogenous
b. rim
c. speckled
d. nucleolar

Answer 22

C